<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="114462">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02111967</url>
  </required_header>
  <id_info>
    <org_study_id>PCRG_Metformin_CMG</org_study_id>
    <nct_id>NCT02111967</nct_id>
  </id_info>
  <brief_title>Study to Identify Adequate Biomarker to Detect Vitamin B12 Deficiency in Type 2 Diabetic Patients Treated With Metformin</brief_title>
  <official_title>Adequacy of Serum Vitamin B12 Meausrement in Type 2 Diabetic Patients Treated With Metformin in Comparison to Holotranscobalamin Measurement</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Basel, Switzerland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Basel</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Solothurner Spit√§ler AG</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Basel, Switzerland</source>
  <oversight_info>
    <authority>Switzerland: Laws and standards</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study we compare the vitamin B12 status by measuring serum vitamin B12 and
      holotranscobalamin in type 2 diabetic patients with and without metformin treatment.
      Afterwars we investigate which biomarker could be adequate to reflect B12 status in
      metformin-treated patients.

      With the help of a questionnaire we assess clinical, nutritional and demographic factors
      which are associated with vitamin B12 deficiency.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">June 2014</completion_date>
  <primary_completion_date type="Anticipated">May 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Case Control, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Measurements of serum vitamin B12 and serum holotranscobalamin concentrations</measure>
    <time_frame>day 3</time_frame>
    <safety_issue>No</safety_issue>
    <description>VB12, HoloTc</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Questionnaire results</measure>
    <time_frame>day 8</time_frame>
    <safety_issue>No</safety_issue>
    <description>Clinical, nutritional and demographic factors which are associated with vitamin B12 deficiency  should be determined in patients with T2DM.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Diabetes Mellitus Type 2</condition>
  <arm_group>
    <arm_group_label>Diabetes mellitus type 2, Metformin</arm_group_label>
    <description>The case group consists of patients with diagnosed diabetes mellitus type 2 treated with Metformin.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Diabetes mellitus type 2</arm_group_label>
    <description>The control group consists of patients with diagnosed diabetes mellitus type 2 which do not have metformin treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Questionnaire administration</intervention_name>
    <arm_group_label>Diabetes mellitus type 2, Metformin</arm_group_label>
    <arm_group_label>Diabetes mellitus type 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory biomarker analysis</intervention_name>
    <arm_group_label>Diabetes mellitus type 2, Metformin</arm_group_label>
    <arm_group_label>Diabetes mellitus type 2</arm_group_label>
  </intervention>
  <biospec_retention>None Retained</biospec_retention>
  <biospec_descr>
    <textblock>
      All blood samples investigated in this study will be destroyed one week after withdrawal.
      All patient information obtained as a result of the study will be regarded as confidential
      and made anonymous using a unique study ID number instead of name and surname of the
      patient.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with diabetes mellitus type 2 treated with and without Metformin.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of T2DM &gt; 6 months

          -  Metformin treatment for at least 6 months

          -  Age &gt; 18 years

          -  Ability to give written informed consent

          -  No metformin treatment in the last 6 months (control group)

        Exclusion Criteria:

          -  Concurrent intake of preparations containing VB12 (within the last 3 months prior to
             study participation)

          -  Lack of written and/or oral understanding in German, French, Italian or English
             languages

          -  Diagnosis of Transcobolamin transporter defect

          -  Diagnosis of Chronic or acute liver diseaseliver insufficiency with CHILD-PUGH scores
             B and C and acute hepatitis

          -  Diagnosis of Renal disease (Creatinine-Clearance &lt;60 ml/min)renal insufficiency
             stadium III, IV and V (KDOQI) and acute renal diseases
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kurt E Hersberger, Prof.</last_name>
    <role>Study Chair</role>
    <affiliation>Pharmaceutical Care Research Group</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Philipp N Walter, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pharmaceutical Care Research Group</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gottfried Rudofsky, Prof. Dr.</last_name>
    <role>Study Director</role>
    <affiliation>Kantonsspital Olten</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Philipp N Walter, Dr.</last_name>
    <phone>062 311 48 19</phone>
    <email>philipp.walter@unibas.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Corina Metaxas, MSc</last_name>
    <phone>061 267 15 19</phone>
    <email>corina.metaxas@unibas.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Pharmaceutical Care Research Group</name>
      <address>
        <city>Basel</city>
        <zip>4056</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philipp Walter, Dr.</last_name>
      <phone>062 311 48 19</phone>
      <email>philipp.walter@unibas.ch</email>
    </contact>
    <contact_backup>
      <last_name>Corina Metaxas, Msc</last_name>
      <phone>061 267 15 19</phone>
      <email>corina.metaxas@unibas.ch</email>
    </contact_backup>
    <investigator>
      <last_name>Philipp N Walter, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 9, 2014</lastchanged_date>
  <firstreceived_date>April 9, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Basel</investigator_affiliation>
    <investigator_full_name>Philipp Walter, PhD</investigator_full_name>
    <investigator_title>Dr.</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Vitamin B 12 Deficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Vitamin B 12</mesh_term>
    <mesh_term>Hydroxocobalamin</mesh_term>
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
